RxDoctor Payments DataLook up a doctor →

Andrew Johnson, MD

Medical Oncology · Gainesville, GANPI 1497045553

Payments from drug & device makers

$252,176in general payments, 2019–2025

Across 922 payments — averaging $273.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$219K
  • Astrazeneca UK Limited$11K
  • AstraZeneca$3K
  • Novartis$2K
  • Seagen Inc.$2K
  • Merck$1K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen16$218,861
Astrazeneca UK Limited1$11,322
AstraZeneca(2 entities)61$3,129
Novartis68$2,051
Seagen Inc.33$1,807
Merck62$1,265
Pfizer68$1,163
Bristol Myers Squibb44$866
Johnson & Johnson32$825
E.r. Squibb & Sons, L.L.C.44$756
Incyte Corporation35$697
Daiichi Sankyo Inc.38$695
AbbVie28$624
Exelixis Inc.22$474
Eisai Inc.21$461
Sanofi20$408
Pharmacyclics LLC, An Abbvie Company20$401
Genentech USA, Inc.22$383
Astellas Pharma US Inc11$373
Regeneron Healthcare Solutions, Inc.17$364
Bayer15$335
Gilead(2 entities)18$322
Lilly USA, LLC14$318
GSK12$289
Takeda Pharmaceuticals U.S.A., Inc.12$285
Array Biopharma Inc24$276
Jazz Pharmaceuticals Inc.12$269
Tersera Therapeutics LLC10$223
Octapharma USA, Inc.2$212
EMD Serono, Inc.10$193
Rigel Pharmaceuticals, Inc.9$180
Puma Biotechnology, Inc.9$170
Stemline Therapeutics Inc.6$131
Boehringer Ingelheim5$118
Epizyme, Inc.7$115
Acrotech Biopharma Inc.7$113
Blueprint Medicines Corporation5$91
Deciphera Pharmaceuticals Inc.5$91
Kyowa Kirin, Inc.4$78
AVEO Pharmaceuticals, Inc.3$70
Sun Pharmaceutical Industries Inc.3$69
Caris MPI, Inc.3$65
Taiho Oncology, Inc.3$64
Foundation Medicine, Inc.3$62
Karyopharm Therapeutics Inc.3$61
Coherus Oncology, Inc.4$61
Geron Corporation3$59
Beigene USA, Inc.3$58
Dova Pharmaceuticals3$55
Sobi, Inc3$54
Tempus AI, Inc2$52
Agios Pharmaceuticals, Inc.3$51
Servier Pharmaceuticals LLC3$51
Pharmaessentia USA Corporation2$42
Tolmar Pharmaceuticals, Inc.2$40
Lexicon Pharmaceuticals, Inc.2$39
Beone Medicines USA, Inc.2$38
Myovant Sciences Inc.2$38
Acceleron Pharma, Inc.2$37
Adaptive Biotechnologies Corporation1$30

How this compares

$252,176 in reported general payments places this provider in the 65th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024
$3,455,613
Medicare patients
448
Services billed
153,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Gainesville

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →